Winston Tan1, Stephen Boorjian2, Pooja Advani3, Sara Farmer4, Christine Lohse4, John Cheville5, Eugene Kwon2, Bradley Leibovich2. 1. Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL. Electronic address: tan.winston@mayo.edu. 2. Department of Urology, Mayo Clinic, Rochester, MN. 3. Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL. 4. Division of Biostatistics, Mayo Clinic, Rochester, MN. 5. Division of Laboratory Medicine and Pathology, Department of Anatomic Pathology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. METHODS: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0%) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. RESULTS: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10% (range, 10%-50%). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90% (range, 20%-100%). Nearly all cases had ER-β expression of ≥ 90% (175 [55.9%] with 90% and 103 [32.9%] with 100%). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5%), 167 (53.4%), and 82 (26.2%) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. CONCLUSIONS: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.
OBJECTIVE:Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth and progression that are important in bladder cancer development. Recently, the estrogen pathway has been found to be a potential target for therapy. METHODS: We identified 410 patients treated with radical cystectomy for urothelial cell carcinoma between 1990 and 1994. We obtained representative paraffin-embedded tissue blocks for 336 (82.0%) of these cases and evaluated the expression and intensity of estrogen receptor (ER)-α, ER-β, and progesterone receptor by immunohistochemistry. RESULTS: Among the 12 ER-α-positive cases, median tumor ER-α expression was 10% (range, 10%-50%). In contrast to ER-α, all cases were ER-β-positive. Median tumor ER-β expression was 90% (range, 20%-100%). Nearly all cases had ER-β expression of ≥ 90% (175 [55.9%] with 90% and 103 [32.9%] with 100%). However, the intensity of ER-β staining varied from focal to moderate to marked in 64 (20.5%), 167 (53.4%), and 82 (26.2%) cases, respectively. Progesterone receptor expression was noted to be negative in all cases. CONCLUSIONS: ER-β is highly expressed in bladder cancer. Prospective validation of these data might further elucidate the utility of ER-β as a marker for prognosis or possible target for therapy.
Authors: Sania Amr; Beverly J Wolpert; Diane Marie St George; India James; Christopher A Loffredo Journal: Cancer Causes Control Date: 2019-01-21 Impact factor: 2.506
Authors: Johannes Breyer; Ralph M Wirtz; Mark Laible; Kornelia Schlombs; Philipp Erben; Maximilian Christian Kriegmair; Robert Stoehr; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann; Wolfgang Otto Journal: Virchows Arch Date: 2016-08-11 Impact factor: 4.064
Authors: M C Kriegmair; R M Wirtz; T S Worst; J Breyer; M Ritter; B Keck; C Boehmer; W Otto; M Eckstein; C A Weis; A Hartmann; C Bolenz; P Erben Journal: Transl Oncol Date: 2018-02-23 Impact factor: 4.243